News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Adolor Corporation Expands Phase 2 Opioid Induced Constipation Program
January 10, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(BUSINESS WIRE)--Adolor Corporation (NasdaqGM: ADLR) today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Gene editing
Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study
May 26, 2026
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
May 22, 2026
·
3 min read
·
Annalee Armstrong
Parkinson’s disease
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
May 22, 2026
·
2 min read
·
Tristan Manalac
Postmarket research
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
May 21, 2026
·
3 min read
·
Tristan Manalac
